The Demy-Colton Virtual Salon Series brings cutting-edge insights from key opinion leaders in the life sciences and digital health industry. The webinar-based series includes: BioFuture, Meet the Disruptors, NYC Biotech Spotlight, and Biotech CEO Summit series.             

July 29, 2020
11:00 am ET

Advanced therapeutics, including gene and call therapies, have emerged as significant FDA/EMA approved therapies for several ultra-rare genetic disorders and advanced malignancies.  In the next couple years, many more will be seeking registration using validated in-vivo and ex-vivo gene transfer and modification platforms (AAV, lentiviral, oligonucleotides, gene editing nucleases, etc.) earning a significant role in the healthcare pharmacopeia.  However, while hurdles such as regulation, manufacturing costs, logistics, and reimbursement have limited patient access, pioneers in the gene therapy sector have been reshaping what healthcare delivery looks like for the next wave of innovators. This BioFuture Salon will discuss the state of the art and potential for gene therapies to become more “drug-like” and scalable for either the personalized ultra-rare or more common chronic disorders.

Please click here to register.
Sara Jane Demy
Michael C. Rice
Faraz Ali

Geoff McDonough
Sapan Shah



September 9, 2020
11:00 am ET



Alzheimer’s disease is a relentless, fatal disease creating a health crisis for patients, families, and nations. If we can’t stop it, the cost to society will be great. Global thought leaders have aligned around a goal to have a treatment that will slow the progression of the disease by 2025. While there have been no positive late-stage studies of investigational medicines in the last decade, the scientific advancement and understanding of AD progression and diagnosis has shifted our knowledge of the disease significantly and led to increased drug development targeting populations in the earliest stages of disease. This evolving scientific understanding of Alzheimer’s disease and the promise that treating earlier than we do today will translate to better patient outcomes.

Please click here to view on demand.

Sara Jane Demy
Phyllis Barkman Ferrell
Dr. Mylea Charvat
Dr. Howard Fillit
Prof. Craig Ritchie

It is estimated that up to 85% of the human proteome is currently "undruggable." These proteins lack easy-to-find pockets where therapeutics can bind. A wave of biotech companies with new technologies have arrived to tackle the problem to overcome the most elusive drug targets.

Please click here to view on demand.

Sara Jane Demy 
Robert J. Schneider 
Abraham Heifets
Marian Nakada
Noam Solomon
Alice Zhang

Two industry titans will explore the metamorphosis that is unfolding in health care, driven by innovation and demanded by consumers, that will profoundly transform this space as we know it. 

Please click here to view on demand.


Sara Jane Demy
Jeremy Abbate
Ralph Snyderman